Literature DB >> 9174216

Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis.

A Filosa1, S Di Maio, S Vocca, A Saviano, G Esposito, L Pagano.   

Abstract

The changes in bone mineral density (BMD) measured by single photon absorptiometry (SPA) using two observations conducted over a period of 2 years were examined in 54 thalassemic subjects [30 F(A) and 24 M(B)] with a chronological age ranging from 2.6 to 22.6 years and in 27 sex- and age-matched controls (C). Each category (A, B and C) was divided into three groups according to pubertal signs: pre-pubertal subjects (A1, B1 and C1); peri-pubertal subjects (A2, B2 and C2) and pubertal subjects from the first observation (A3, B3 and C3). Furthermore, each group of patients was divided into sub-groups on the basis of haematological phenotypes, those with a more severe form were called beta0/beta0 while those with other forms were called "others". The most significant findings were the following: the presence of a more severe reduction of the bone mineral density in patients with the beta0/beta0 phenotype than in patients with the "others" phenotype; patients with hypogonadism corresponded to the beta0/beta0 phenotype, while those with spontaneous puberty corresponded to the "others" phenotype. In conclusion, since puberty and the degree of bone mineral density are related to the haematological phenotype, puberty (spontaneous or induced) positively influences the bone mineral density only at the start of puberty, while subsequently, the degree of osteoporosis is the expression of widespread and chronic systemic damage due to the haematological phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174216     DOI: 10.1111/j.1651-2227.1997.tb09019.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  12 in total

1.  Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.

Authors:  A Sartorio; G Conte; A Conti; A Masala; S Alagna; P Rovasio; G Faglia
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

2.  Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.

Authors:  Nicholas G Angelopoulos; Anastasia Goula; Grigorios Rombopoulos; Victoria Kaltzidou; Eugenia Katounda; Dimitrios Kaltsas; George Tolis
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Hypoparathyroidism in adult patients with Beta-thalassemia major.

Authors:  Gihan Ali A M Sleem; Ibrahim S Al-Zakwani; Muhanna Almuslahi
Journal:  Sultan Qaboos Univ Med J       Date:  2007-12

4.  Endocrine and metabolic disorders in β-thalassemiamajor patients.

Authors:  Fatemeh Saffari; Abolfazl Mahyar; Shabnam Jalilolgadr
Journal:  Caspian J Intern Med       Date:  2012

Review 5.  Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major.

Authors:  Fabio Pellegrino; Maria Chiara Zatelli; Marta Bondanelli; Aldo Carnevale; Corrado Cittanti; Monica Fortini; Maria Rita Gamberini; Melchiore Giganti; Maria Rosaria Ambrosio
Journal:  Endocrine       Date:  2019-07-12       Impact factor: 3.633

6.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

7.  Impact of genotype on endocrinal complications in β-thalassemia patients.

Authors:  Ahmed Al-Akhras; Mohamed Badr; Usama El-Safy; Elisabeth Kohne; Tamer Hassan; Hadeel Abdelrahman; Mohamed Mourad; Joaquin Brintrup; Marwa Zakaria
Journal:  Biomed Rep       Date:  2016-04-04

8.  Bone mineral density in thalassemia major patients from antalya, Turkey.

Authors:  Ibrahim Aslan; Duran Canatan; Nihal Balta; Gulizar Kacar; Cengaver Dorak; Ahmet Ozsancak; Nurgul Oguz; Ruya Cosan
Journal:  Int J Endocrinol       Date:  2012-06-20       Impact factor: 3.257

9.  Predictors of bone disease in Egyptian prepubertal children with β-thalassaemia major.

Authors:  Azza A G Tantawy; Eman A El-Bostany; Randa M Matter; Eman A El-Ghoroury; Shadia Ragab
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

10.  Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis.

Authors:  Mohamed A Yassin; Ashraf T Soliman; Vincenzo De Sanctis; Mohamed Osman Abdelrahman; Elsaid M Aziz Bedair; Manal AbdelGawad
Journal:  Indian J Endocrinol Metab       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.